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Ultrasound Mediated Destruction of DNA-Loaded
Microbubbles for Enhancement of Cell-Based Therapies
New Promise Amidst a Conﬂuence of Uncertainties?*
Flordeliza S. Villanueva, MD
Pittsburgh, PennsylvaniaUltrasound contrast agents in current clinical use
are small (1 to 4 m) gas-filled “microbubbles”
comprised of a perfluorocarbon gas that is encap-
sulated by a biocompatible shell (1). They freely
transit through the microcirculation; high-powered
ultrasound can be used to selectively destroy these
microbubbles, with consequent release of their con-
tents into the organ of interest. This acoustic
responsiveness of microbubbles has been exploited,
See page 869
to great promise, for the targeted delivery of genes
that are incorporated into the microbubble shell
prior to systemic injection. The hypothesis is that
destruction of deoxyribonucleic acid-loaded micro-
bubbles by a focused ultrasound beam during their
microvascular transit through the target area will
cause localized release of the genes upon disruption
of the microbubble shell, sparing nontarget areas,
while concentrating the payload to the site of in-
tended treatment. However, the exact mechanisms
of gene incorporation are somewhat unclear (2).
Mechanistic uncertainties notwithstanding, us-
ing microbubbles as vectors for delivering plasmid
deoxyribonucleic acid poses several advantages: The
method appears to be safe, easy and can be repeated;
plasmids in bubbles resist degradation in blood, can
be targeted to the intended treatment site, and
avoid safety issues of other gene delivery systems
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the University of Pittsburgh School of Medicine, Cardiovascular
Institute, Center for Ultrasound Molecular Imaging and Therapeutics,
Pittsburgh, Pennsylvania. Dr. Villanueva is supported in part by the
National Institutes of Health (HL RO1HL077534-01).(3,4). Efficacy of ultrasound-targeted microbubble
destruction (UTMD)-mediated gene delivery has
been proven in animal studies using various types of
microbubble preparations and reporter gene con-
structs in different organ systems (4–11). Early
studies demonstrated capacity to safely deliver and
direct reporter gene expression in the heart (5,6)
and other tissues (7). Fewer studies have extended
UTMD to the delivery of therapeutic genes into the
heart (8). Interestingly, while the concept of
UTMD-directed gene delivery was first proven in
the heart, cardiac applications appear to have since
been “left out” from subsequent studies examining
clinically relevant therapeutic effects of this delivery
method. Focus seems to have migrated to extra-
cardiac applications (9–11).
So why does the heart appear to be excluded from
the recent momentum for UTMD-mediated gene
therapy? Some clues emerge when examining initial
reporter gene studies with UTMD for the heart,
mostly using luciferase plasmid driven by a cyto-
megalovirus promoter, in which transgene expres-
sion is quantified in relative light units (RLU).
Cardiac expression of luciferase after UTMD-
mediated gene therapy seems to be inefficient; peak
expression varies from 1,000 to about 3,500
RLU/min/mg protein (6) compared to luciferase
transgene expression on the order of 105 RLU/
min/gm (12) in noncardiac tissue when delivered
via other nonviral vectors (these methods have not
as yet been directly compared with UTMD-
mediated gene delivery). Whether this low effi-
ciency for heart transduction is due to the promoter,
technical fallacies in the application of UTMD,
differences in the extent of plasmid incorporation
into the microbubble shell resulting from varying
microbubble synthesis protocols, and/or inherent
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881ifferences in organ susceptibility to microbubble-
ediated gene therapy is unclear, but highlights
ow little we know about the mechanisms by which
ltrasound destruction of plasmid-bearing micro-
ubbles really works.
In this issue of iJACC, Fujii et al. (13) rekindle
nthusiasm for UTMD-directed gene therapy for
he heart. The authors apply this approach to
ddress a challenge encountered in cell-based ther-
pies for the heart; namely limited cell engraftment
fter exogenous delivery of reparative cells, and seek
o test the general hypothesis that improving the
icroenvironment supporting exogenously deliv-
red cells will improve cell engraftment. In distinc-
ion to previous studies, mice were used, and a
yocardial infarction model of chronic total coro-
ary occlusion was employed as the disease model.
lso unique was the selection, for one of the
xperimental groups, of plasmid encoding for stem
ell factor (SCF) as the therapeutic gene. Separate
roups of mice with chronic coronary occlusion
ere intravenously administered microbubbles
earing plasmid for green fluorescent protein
GFP), vascular endothelial growth factor165
VEGF165), SCF, or blank plasmid, and hearts
ere exposed to UTMD using a clinical echocar-
iographic scanner. Fluorescent microscopy con-
rmed expression of the GFP, although the mag-
itude (% of cells) and site of the expression (infarct
s. noninfarct zone) and the transfected cell type(s)
re not reported. Relative to controls, SCF levels
ere higher in the region remote from the infarct,
hereas VEGF levels were higher in the infarct
one, but it is difficult to parcel out how much of
ach protein was increased due to the infarct model
ersus incremental expression by the transgene it-
elf. Histologic analysis showed increased microvas-
ular density in the treated groups, although it is
ot stated whether this occurred in the infarct or
emote zone. Remarkably, 2-dimensional echocar-
iographic data indicated treatment-related de-
reases in infarct expansion and infarct thickness
nd significant improvements in left ventricular
ystolic function and perfusion.
This is an ambitious study with ambitious results.
t is an ambitious undertaking because the study
pplies a mechanistically poorly understood tech-
ology of UTMD to the heart, which has been
istorically difficult to transfect with this technique.
nd even more ambitious because it applies this
edgling gene delivery strategy to areas that are
hemselves bedeviled by fundamental mechanistic
ncertainties and treatment conundrums, namely deparative cell therapy and attenuation of adverse
eft ventricular remodeling. That this confluence of
ncertainties should result in such a dramatic bio-
ogic effect with significant clinical therapeutic im-
lications is remarkable and should be cause for
oth optimism as well as healthy skepticism.
Some of the data in this study are difficult to
ausally connect in a physiologically coherent way
nd call for cautious interpretation and analysis of
hy the clinical effects were so dramatic. The
esults are all the more remarkable given that
he dose of plasmid, when considering the
icrobubble-plasmid attachment protocol used,
as likely less than that used in prior reporter gene
tudies (6). An easy explanation might be that the
ouse myocardial model is more susceptible to
TMD-directed gene therapy than previously used
at models, and that there is species-specific heter-
geneity in responsiveness to gene transduction by
lasmid-bearing microbubbles. Another possible
xplanation is that even slight transgene expression
as adequate to initiate a cascade of events which
riggered downstream events that ultimately caused
functionally measurable physiologic response.
While plausible, such explanations are unlikely to
ccount for the entire effect, and other features of
he study merit mention in this regard. It should be
oted, for example, that a model of chronic total
cclusion was used. Since mice do not have abun-
ant pre-formed collaterals, the microbubbles
ould have limited access to the infarct territory.
his implies, therefore, that the “active ingredients”
ediating the therapeutic effects must have, at least
nitially, emanated from the remote, noninfarct
erritory, which then raises mechanistic questions as
o how events in a distant region mediated the
herapeutic events in the infarct zone. One possible
xplanation suggested by the authors is that the
reatment recruited “progenitor” cells, particularly
ince SCF, which recruits c-kit cells, was ex-
ressed more in the remote zone than the infarct
one. That SCF expression was higher in the
emote zone makes sense given the greater access of
icrobubbles to the nonoccluded coronary artery
erritory. However, it is not so clear whether “pro-
enitor cells” were mobilized, as the flow cytometry
ata presented were somewhat equivocal as to the
resence of discrete subpopulations of c-kit cells.
lso, c-kit cells in the heart could be bone
arrow-derived endothelial progenitor cells, circu-
ating endothelial progenitor cells and or resident
ardiac progenitor cells (14), and it would be
ifficult to speculate what reparative processes could
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882ave been set in motion as a function of a specific
rogenitor cell type. It is also difficult to reconcile
ow UTMD increased VEGF165 levels only in the
nfarct zone, since microbubbles would have im-
eded access to the infarct territory in the setting of
otal coronary occlusion.
Overall, this study generates both optimism as
ell as caution for using plasmid-carrying micro-
ubbles to produce clinically relevant biological
ffects on the heart using UTMD. The investiga-
ion is certainly hypothesis-generating, and creates
need to perform additional studies to shed greater
ight on some of the issues mentioned earlier. The
uestions raised by this study underscore how much
emains to be learned about the mechanisms and
ffects of microbubble-mediated gene therapy, and
herefore, how relatively little we know about ways
o optimize the results. The myriad unknowns
ccompanying the mechanisms of myocardial repair
nd regeneration, ventricular remodeling, and an-
iogenesis, among the phenomena touched on by
his study, and the interdependence of these phe-
omena, make a gene-therapy approach to augment
ny of these processes—by any vector—challenging2000;101:2554–6. Gene Ther 2007;14antages of UTMD-mediated gene therapy warrant
ragmatic studies to standardize and optimize pro-
ocols, as well as further systematic exploration of
ts efficacy, mechanisms of action, and clinical
ndications. As to the specific goal of Fujii et al. (13)
o enhance the local intramyocardial milieu for
herapeutic cell engraftment, the next step would be
o determine whether their UTMD protocol actu-
lly improves engraftment of exogenously delivered
ells, although if the dramatic therapeutic effects
eported in this study are reproduced, the need to
ctually deliver additional reparative cells may even
e obviated.
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